JP2017505127A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505127A5 JP2017505127A5 JP2016548101A JP2016548101A JP2017505127A5 JP 2017505127 A5 JP2017505127 A5 JP 2017505127A5 JP 2016548101 A JP2016548101 A JP 2016548101A JP 2016548101 A JP2016548101 A JP 2016548101A JP 2017505127 A5 JP2017505127 A5 JP 2017505127A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- cell
- locus
- cells
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 31
- 241000699666 Mus <mouse, genus> Species 0.000 claims 12
- 108010091086 Recombinases Proteins 0.000 claims 8
- 102000018120 Recombinases Human genes 0.000 claims 8
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 241000699670 Mus sp. Species 0.000 claims 6
- 210000001671 embryonic stem cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 210000002459 blastocyst Anatomy 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 108091033409 CRISPR Proteins 0.000 claims 2
- 108010051219 Cre recombinase Proteins 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108700029233 VDJ Exons Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000003844 B-cell-activation Effects 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003297 immature b lymphocyte Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 210000003519 mature b lymphocyte Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931074P | 2014-01-24 | 2014-01-24 | |
| US61/931,074 | 2014-01-24 | ||
| PCT/US2015/012577 WO2015112790A2 (en) | 2014-01-24 | 2015-01-23 | High-throughput mouse model for optimizing antibody affinities |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505127A JP2017505127A (ja) | 2017-02-16 |
| JP2017505127A5 true JP2017505127A5 (OSRAM) | 2018-03-01 |
| JP6479024B2 JP6479024B2 (ja) | 2019-03-06 |
Family
ID=53682124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016548101A Active JP6479024B2 (ja) | 2014-01-24 | 2015-01-23 | 抗体親和性の最適化のための高スループットマウスモデル |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10034463B2 (OSRAM) |
| EP (1) | EP3096609B1 (OSRAM) |
| JP (1) | JP6479024B2 (OSRAM) |
| WO (1) | WO2015112790A2 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
| AU2011286185B2 (en) | 2010-07-26 | 2014-08-14 | Trianni, Inc. | Transgenic animals and methods of use |
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| RS62263B1 (sr) | 2013-04-16 | 2021-09-30 | Regeneron Pharma | Ciljana modifikacija genoma pacova |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| PT3066201T (pt) | 2013-11-07 | 2018-06-04 | Massachusetts Inst Technology | Métodos e composições relacionadas com crispr com arng reguladores |
| RU2725520C2 (ru) | 2013-12-11 | 2020-07-02 | Регенерон Фармасьютикалс, Инк. | Способы и композиции для направленной модификации генома |
| US9068179B1 (en) | 2013-12-12 | 2015-06-30 | President And Fellows Of Harvard College | Methods for correcting presenilin point mutations |
| US10034463B2 (en) * | 2014-01-24 | 2018-07-31 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL301900A (en) | 2014-11-21 | 2023-06-01 | Regeneron Pharma | Methods and compositions for targeted genetic modification using paired guide rnas |
| EP3365356B1 (en) | 2015-10-23 | 2023-06-28 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
| WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
| US11053288B2 (en) | 2016-02-04 | 2021-07-06 | Trianni, Inc. | Enhanced production of immunoglobulins |
| CA3017678A1 (en) * | 2016-04-04 | 2017-10-12 | Eth Zurich | Mammalian cell line for protein production and library generation |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| EP3497214B1 (en) | 2016-08-09 | 2023-06-28 | President and Fellows of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165631A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| EP3601528A4 (en) * | 2017-03-20 | 2021-05-05 | Washington University | CELLS AND METHODS OF USE AND PRODUCTION OF THEM |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| WO2018204303A1 (en) | 2017-05-01 | 2018-11-08 | The Children's Medical Center Coporation | Methods and compositions relating to anti-pd1 antibody reagents |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CN111757937A (zh) | 2017-10-16 | 2020-10-09 | 布罗德研究所股份有限公司 | 腺苷碱基编辑器的用途 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| WO2019241122A1 (en) * | 2018-06-13 | 2019-12-19 | The Children's Medical Center Corporation | Methods and compositions relating to high-throughput models for antibody discovery and/or optimization |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| WO2020154500A1 (en) | 2019-01-23 | 2020-07-30 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| EP3956349A1 (en) | 2019-04-17 | 2022-02-23 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| MX2022014008A (es) | 2020-05-08 | 2023-02-09 | Broad Inst Inc | Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo. |
| US20240294633A1 (en) * | 2021-06-04 | 2024-09-05 | Nonagen Therapeutics Corporation | Antibody specific for anti-bcl-6 antibody and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6130364A (en) * | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| WO2009143472A2 (en) * | 2008-05-23 | 2009-11-26 | Aliva Biopharmaceuticals, Inc. | Method of generating single vl domain antibodies in transgenic animals |
| RU2011129459A (ru) | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
| MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
| WO2013041844A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| MY172946A (en) * | 2011-10-17 | 2019-12-16 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| HUE055617T2 (hu) * | 2012-06-12 | 2021-12-28 | Regeneron Pharma | Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények |
| US10034463B2 (en) * | 2014-01-24 | 2018-07-31 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
-
2015
- 2015-01-23 US US15/112,557 patent/US10034463B2/en active Active
- 2015-01-23 WO PCT/US2015/012577 patent/WO2015112790A2/en not_active Ceased
- 2015-01-23 JP JP2016548101A patent/JP6479024B2/ja active Active
- 2015-01-23 EP EP15739843.9A patent/EP3096609B1/en active Active
-
2018
- 2018-06-25 US US16/017,221 patent/US11974553B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505127A5 (OSRAM) | ||
| JP6876853B2 (ja) | 動物モデルおよび治療用分子 | |
| US11224207B2 (en) | Non-human animals expressing pH-sensitive immunoglobulin sequences | |
| JP2022090103A (ja) | 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物 | |
| EP2509409B1 (en) | Mice that make heavy chain antibodies | |
| JP2019068857A5 (OSRAM) | ||
| JP2019022518A5 (OSRAM) | ||
| JP2020124228A (ja) | ヒト可変領域を保有している抗体を産生するために有用な繁殖可能遺伝子導入動物 | |
| JP2015510769A5 (OSRAM) | ||
| CN111031789A (zh) | 动物模型和治疗性分子 | |
| CN105695415A (zh) | 动物模型及治疗分子 | |
| RU2016123708A (ru) | Отличные от человека животные, содержащие гуманизированный ген фактора активации в-клеток | |
| JP2014110814A5 (OSRAM) | ||
| EP3046412A1 (en) | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same | |
| WO2015077072A4 (en) | Non-human animals having a humanized a proliferation-inducing ligand gene | |
| Takeuchi et al. | Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting | |
| JP2019506897A5 (OSRAM) | ||
| JP2022538885A (ja) | トランスジェニック哺乳動物およびその使用法 | |
| JP2021166551A (ja) | 鳥類および卵 | |
| JP2021508236A5 (OSRAM) | ||
| JP7765403B2 (ja) | ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物 | |
| WO2017175745A1 (ja) | 生殖細胞欠損動物を用いる遺伝子改変動物の作製方法 | |
| GB2495083A (en) | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates | |
| HK40013873A (en) | Non-human animals expressing ph-sensitive immunoglobulin sequences | |
| Cogné et al. | Marie Marquet, Armand Garot, Sébastien Bender, Claire |